EXEL-2880 |
XL880 |
GSK-1363089G |
GSK1363089G |
XL-880 |
GSK089 |
GSK1363089 |
FORETINIB |
GSK 1363089G |
XL 880 |
chembl:CHEMBL1230609 |
drugbank:12307 |
chemidplus:849217-64-7 |
pubchem.compound:42642645 |
Pharmaceutical Developer | GlaxoSmithKline |
Source Reported Drug Name(s) | GSK1363089 |
Drug Class | MET/VEGFR Inhibitor |
Drug Class | Kinase Inhibitors |
FDA Approval | not approved |
Drug Class | small molecule |
Drug Indications | antineoplastic agent |
Drug Categories | amides |
Drug Categories | amines |
Drug Categories | aniline compounds |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | receptors, vascular endothelial growth factor, antagonists & inhibitors |
Drug Categories | tyrosine kinase inhibitors |
n/a |
Drug family | MET inhibitor |
Alteration | PTCH1:. |
inhibitor (inhibitory) |
Approval Status | Preclinical |
combination therapy | Foretinib + Rucaparib |
Evidence Type | Actionable |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase TIE-2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Stem cell growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
GSK1363089 | PubChem Drug Name |
42642645 | PubChem Drug ID |
Foretinib | Drug Trade Name |
Drug Class | MET/VEGFR Inhibitor |
Source Reported Drug Name(s) | GSK1363089 |
Pharmaceutical Developer | GlaxoSmithKline |
EXEL-2880 | Development Name |
GSK1363089 | Development Name |
XL880 | Development Name |
Drug Class | Kinase Inhibitors |
FORETINIB | DrugBank Drug Name |
849217-64-7 | CAS Number |
CHEMBL1230609 | ChEMBL ID |
Drug Type | small molecule |
Drug Groups | investigational |
Drug Categories | amides |
Drug Indications | antineoplastic agent |
Drug Class | small molecule |
FDA Approval | not approved |
D0D1GF | TTD Drug ID |
FORETINIB | Primary Drug Name |
FORETINIB | Drug Generic Name |
GSK1363089 | Drug Synonym |
CHEMBL1230609 | ChEMBL Drug ID |
FORETINIB | GuideToPharmacology Ligand Name |